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Control of micrometastatic pancreatic cancer remains a major objective in pancreatic cancer treatment. The overexpression of
MUC1 mucin plays an important role in cancer metastasis. The aim of this study was to detect the expression of MUC1 in human
primary tumour tissues and three pancreatic cancer cell lines (CAPAN-1, CFPAC-1 and PANC-1), and target MUC1-positive cancer
cells in vitro using
213Bi-C595 alpha-immunoconjugate (AIC). The expression of MUC1 on pancreatic tumour tissues and cancer cell
lines was performed by immunohistochemistry and further confirmed by confocal microscope and flow cytometry analysis on the cell
surface. Cytotoxicity of
213Bi-C595 was tested by MTS assay. Apoptosis was documented using TUNEL assay. Overexpression of
MUC1 was found in B90% of tested tumour samples and the three pancreatic cancer cell lines.
213Bi-C595 is specifically cytotoxic to
pancreatic cancer cells in a concentration-dependent fashion. These results suggest that overexpression of MUC1 in pancreatic
cancer is a useful target, and that the novel
213Bi-C595 AIC selectively targets pancreatic cancer cells in vitro.
213Bi-C595 may be a
useful agent for the treatment of micrometastases or minimal residual disease (MRD) in pancreatic cancer patients with
overexpression of MUC1 antigen.
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Pancreatic cancer is one of the leading cause of cancer death in the
US, where an estimated 29200 new cases per year will be
diagnosed, and 28900 people will die from the disease (Landis
et al, 1999). The 5-year survival rate is only 5.2% for those who had
no cancer-directed treatment (Sener et al, 1999) and the median
survival is B6 months. Although some improvements in surgical
outcome occur in patients who also receive chemotherapy and/or
radiotherapy, the impact on long-term survival has not changed in
two decades (Sener et al, 1999). The major problem in the
management of postsurgical cases is failure to control cancer
micrometastases. Many carcinoma-associated markers have aber-
rant expression in cancer cells. A monoclonal antibody (MAb) with
high specificity and affinity could be used for targeted therapy, and
may serve to overcome this problem.
MUC1 is a well-documented example of a marker that influences
pathophysiological behaviour. High molecular weight glycopro-
teins, described as mucins or mucin-like glycoproteins, are
frequently found associated with breast carcinoma and other
epithelial cell adenocarcinomas (Zotter et al, 1988). Cancer-
associated MUC1 is structurally different from normal MUC1 in
that the former has shorter and less dense O-glycan chains,
exposing novel regions of the protein core. The large extracellular
domain is dominated by a heavily O-glycosylated region consisting
of a variable number of 20 amino-acid tandem repeats (VNTRs)
(Gendler et al, 1988). The number of these VNTR sequences is
subject to genetic polymorphism, varying between 30 and over 100.
MUC1 function involves mediating cellular transformation in
integrating the growth factor receptor and Wnt signalling
pathways (Ren et al, 2002). MUC1 expression causes anchorage-
independent growth and tumour formation, and is a useful marker
for the prognosis of the patients with carcinoma. Patients with
MUC1 expression in the carcinoma show significantly lower
survival rates than those without MUC1 expression (Kitamura et al,
1996; Utsunomiya et al, 1998).
MAb C595 (also known as NCRC48) is reactive with the protein
core of MUC1 mucin. The target epitope of the MAb C595 is the
tetrameric motif Arg-Pro-Ala-Pro that is repeated many times
within the MUC1 protein core (Gendler et al, 1988; Price et al, 1990).
The reactivity of the MAb C595 with synthetic peptides containing
this motif permits efficient antibody purification using peptide-
epitope affinity chromatography, which, unlike other methodolo-
gies, enables exclusion recovery of functionally active antibody.
MAbs are being realised for their potential in anticancer
therapeutics. It was reported that the most widely explored
strategy for enhancing the efficacy of antitumour antibodies is
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sdirect arming by chelator linkage to toxins or radionuclides (Farah
et al, 1998). However, the evaluation of specific cancer MAbs
remains a major task for antibody-based therapies. MUC1 may
provide a good basis for targeting pancreatic cancer cells in transit
or in preangiogenic cancer cell clusters. MAb C595 has been
labelled with
67Cu and
188Re for radioimmunotherapy in bladder
cancer (Hughes et al, 1997, 2000a; Murray et al, 2001).
Alpha-emitting radionuclides such as
213Bi emit a particles with
energies of 4–8MeV, which are up to an order of magnitude
greater than most b rays. Yet, their ranges are two orders of
magnitude less as a particles have a linear energy transfer (LET)
that is about 100 times greater (Allen, 1999). Since a particles, by
comparison with b particles, have a much shorter path length as
well as a much higher LET, they are significantly more selective
and potent in killing targeted cells (McDevitt and Scheinberg,
2002). Owing to the short path length, little collateral damage may
be inflicted upon nontarget cells, while a single decay of an
internalised a-emitter passing through the nucleus can be lethal
(Sgouros et al, 1999; Jurcic et al, 2002). As a result, a much greater
fraction of the total energy is deposited in cells with a particles and
very few nuclear hits are required to kill a cell. Consequently, a
100-fold enhancement in radiation dose could be delivered to the
nucleus of a cancer cell if a targeted vector is employed to take the
a-radionuclide to that cancer cell.
In the present study, we have demonstrated moderate to strong
MUC1 expression on the majority of human primary pancreatic
tumours and pancreatic cancer cell lines using MAb C595. We also
evaluated an anticancer effect of
213Bi-C595 against human
pancreatic cells in vitro. We suggest that
213Bi-C595 may have
the potential to target micrometastatic pancreatic cancer cells with
MUC1 overexpression and represent a new therapeutic modality
for the control of pancreatic cancer metastases.
MATERIALS AND METHODS
Monoclonal antibodies
C595 MAb was obtained from Nottingham University, UK. A
nonspecific control IgG1 MAb (know as A2, offered MOPC) was
provided by Professor A Collins (University of New South Wales,
Australia). Rabbit anti-mouse IgG conjugated to HRP and mouse
IgG1 negative control MAb were purchased from Dakopatts
(Glostrup, Denmark). Goat anti-mouse-fluorescein isothiocyanate
(FITC) MAb was purchased from Silenus (Sydney, NSW,
Australia). Alexa Fluor 488 goat anti-mouse IgG MAb was
purchased from Molecular Probes (Eugene, OR, USA).
Human pancreatic tumour tissues
Following institutional approval from the Northern Sydney Health
Human Research Ethics Committee, informed consent was
obtained from 53 patients (male: 31, female: 22; age range 41–
81years, average 68.7 years) undergoing pancreatic resection for a
pancreatic mass at Royal North Shore Hospital, NSW, Australia.
Tumour sections included normal pancreatic tissue. Slides from
paraffin sections were prepared for H&E staining and immunos-
taining.
Immunohistochemistry
MUC1 expression was detected by immunohistochemistry. Briefly,
paraffin-embedded tissues were cut at 5mm sections, mounted on
gelatine-coated glass slides and then incubated for 20min at 601C.
The slides were deparaffinised in xylene, followed by a graded
series of alcohols (100, 95 and 75%) and rehydrated in Tris-buffer
saline (TBS, PH 7.5). The following steps were performed at room
temperature (RT). The primary C595 MAb (13.0mgml
 1) was
incubated for 1h. After washing with TBS, slides were incubated
with HRP-conjugated rabbit anti-mouse IgG (6.5mgml
 1) for
45min and then washed with TBS two times, and developed with
diamino benzoate (DAB) substrate solution for 5–10min. The
criteria for assessment are to combine staining intensity with
percentage of positive cancer cells as follows:  , o25%; þ (weak),
25–50%; þþ (moderate), 50–75%; þþþ (strong), 475% of
the neoplastic cells stained. An average of the grades for two
independent observers is taken.
Cell culture
The human pancreatic cell lines (CAPAN-1, CFPAC-1 and PANC-
1) were purchased from American Type Culture Collection (ATCC,
Rockville, MD, USA). CAPAN-1 and CFPAC-1 cells are cultured in
Iscove’s modified Dulbecco’s medium supplemented with 20 and
10% (vv
 1) heated-inactivated fetal bovine serum (FBS), 50Uml
 1
penicillin and 50Uml
 1 streptomycin, respectively. PANC-1 cells
are cultured in Dulbecco’s modified eagle’s medium supplemented
with 10% FBS, 50Uml
 1 penicillin and 50Uml
 1 streptomycin.
All tissue culture reagents were supplied by Life Technologies Inc.
(Grand Island, NY, USA), unless otherwise stated. Three cell lines
were maintained in a humidified incubator at 371C and 5% CO2
and detached with Dulbecco’s phosphate-buffer saline (DPBS)/
trypsin (0.25%)/ethylene diammine tetraacetic acid (EDTA)
(0.05%) at 371C for 5–10min.
Immunocytochemistry
An indirect conjugated peroxidase method was used to detect the
expression of MUC1 on CAPAN-1, CFPAC-1 and PANC-1
pancreatic cancer cell lines as described previously (Li et al, 2002).
Confocal microscope for MUC1 expression
1 10
5 cultured cells including CAPAN-1, CFPAC-1 and PANC-1
were grown on coverslips. After washing with PBS, the cells were
fixed on coverslips in ice-cold acetone for 10min. C595 MAb
(13.0mgml
 1) was incubated for 12h at 41C or for 2h at RT on a
shaking table and rinsed with PBS. Thereafter, a goat-anti-mouse-
conjugated Alexa 488 green antibody (1:100 dilution) was added
for 1h at RT, rinsed in PBS for 10–15min. The slides were
mounted with coverslips using glycerol (Sigma-Aldrich Pty,
Limited, Castle Hill, NSW, Australia). Examination was performed
with Confocal Microscope (FV300/FV500 Olympus, Japan).
Flow cytometry
Indirect immunofluorescence imaging counter was performed to
detect cell-surface expression of MUC1 in CAPAN-1, CFPAC-1 and
PANC-1 pancreatic cancer cell lines as described previously (Li
et al, 2002).
Preparation of a conjugates
213Bi has a short half-life (t1/2¼46min), short range (80mm) and
emits an a particle with energy of 8MeV.
213Bi was eluted from the
225Ac/
213Bi column, which was supplied by the Institute for
Transuranium Elements (ITU), Germany, with 250ml of freshly
prepared 0.15 M hydriodic acid (HI) as the (BiI5)
2  anion species,
neutralised to pH 4–4.5 with the addition of 3 M ammonium
acetate and immediately used to radiolabel the MAb construct
(Boll et al, 1997). A time of 2–3h was allowed for
213Bi to grow
back in the generator for the next elution. C595 and A2 MAbs were
conjugated with the chelator, cyclic diethylenetriaminepentacetic
acid anhydride (cDTPA) (Sigma-Aldrich Pty, Limited, Castle Hill,
NSW, Australia), using published methods (Abbas Rizvi et al,
2000). The conjugated C595 and A2 were measured by plate
reader at 280nm wavelength using ProMax software (Bio-TEC
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sInstruments Inc., Winooski, Vermont, USA), and purified on a PD-
10 column (Amersham Biosciences Pty Limited, Castle Hill, NSW,
Australia). Alpha-immunoconjugates of each antibody were
obtained by labelling with free
213Bi for 20min at RT. The
radiolabelling efficiency was determined by instant thin layer
chromatography (ITLC) using a Gelman paper (Gelman Science
Inc., Ann Arbor, MI, USA). Briefly, a 10ml aliquot of the final
reaction mixture was applied to Gelman paper. The paper strips
were developed using 0.5 M sodium acetate (pH 5.5) as the solvent.
The paper strips were cut into four sections and the gamma
emissions from the radioisotope in each section were counted
using a 340–540keV window. The radiolabelled protein stayed at
the origin section, while free radioisotope moved with the solvent
front section. The labelling efficiency of AICs was B93%. Specific
activity was in the range 1–1.5mCimg
 1.
In vitro cell cytotoxicity
An MTS assay was used to test cell cytotoxicity after treatment.
Cultured CAPAN-1, CFPAC-1 and PANC-1 pancreatic cancer
cells were washed twice with DPBS and seeded into 96-well
flat-bottomed plates at a density of 2 10
4 cells in 100mli n
RPMI-1640 medium plus 5% FBS. The activity of
213Bi-C595 (test)
and
213Bi-A2 (control) preparations was measured using a radio-
isotope calibrator (Biodex Medical System ATOMLAB 200, Shirley,
NY, USA) and neutralised to pH 7.0 via the addition of 10% (vv
 1)
1 M NaHCO3 (pH 9.0). After this, six serial activities of
213Bi-C595
AIC (1B10mCi) were added to each well in triplicate. Controls
included nonspecific
213Bi-A2 (10mCi), cDTPA-C595, C595 MAb
alone or cell alone (no treatment) were also performed in triplicate
in the same 96-well plate for each experiment. The plates were
then incubated o/n in a 5% CO2 atmosphere at 371C. The cells
were then washed and incubated with 100ml phenol-red free
medium (without FBS) containing 20ml of the cellTiter 96 Aqueous
One Solution reagents (Promega, Madison, WI, USA). After a
3h incubation in a 5% CO2 atmosphere at 371C, the reaction
was stopped by the addition of 10% SDS, and the absorbance
in each well was recorded at 490nm using a SPECTRO max
plate reader (BIO-RAD, Hercules, CA, USA). The absorbance
reflects the number of surviving cells. Blanks were subtracted
from all data and analysed using Prism software (GraphPad
Software Inc., USA).
TUNEL assay
A TUNEL assay was performed to investigate whether the
lethal pathway is through apoptosis after treatment with
213Bi-C595. Briefly, CAPAN-1, CFPAC-1 and PANC-1 pancreatic
cancer cells were cultured in six-well plates and incubated
in medium as described above. The cultured cells were treated
with
213Bi-C595 AIC in a concentration of 1mCi10
4 cells
 1 or
with nonspecific control AIC
213Bi-A2 at the same concentration,
and media alone at 371C for 4, 8, 12, 24, 48 and 72h. After
treatment, the cells were washed with DPBS, harvested by
centrifugation of the washing DPBS and slides were made by
cytospin. Apoptosis cells were detected using the TUNEL method
(Gavrieli et al, 1992) with TdT-fragELt in situ apoptotic detection
kit according to the manufacturer’s instructions (Oncogene
Research Products, Boston, MA, USA). Specificity of TUNEL
reactivity was confirmed by undertaking in parallel appropriate
negative (omitting TdT from the labelling mix) and positive
(treated HL-60 slides) controls. Cells with three or more nuclear
chromatin fragments were considered as positive apoptosis. The
labelled cells were examined using a Leica light microscope (Leica
microscope, Nussloch, Germany) at  40 magnifications. The
results were expressed as a percentage of total cells staining
positive for apoptosis.
RESULTS
Expression of MUC1 on human pancreatic cancer tissues
Immunoreactivity identified in pancreatic cancer tissues using
paraffin section stained with MAb C595 is summarised in Table 1.
Typical staining results are shown in Figure 1. Strong MUC1
expression was found in 28 out of 53 (53%) tested samples
(Figure 1A, patient 1). Moderate MUC-1 expression was found in
15 out of 53 (28.4%) (Figure 1B, patient 2), and weak expression in
five out of 53 (9.4%) samples. No significant expression of MUC1
was found in five out of 53 (9.4%) samples. The control A2 MAb
was negative to pancreatic cancer section (Figure 1C). Normal
tissues were not detected with immunoreactivity in 50 out of 53
(94.6%) (Figure 1D). Only three samples with weak immuno-
reactivity were detected in the normal part of the pancreatic gland.
Expression of MUC1 in pancreatic cancer cell lines
The immunoreactivity of the three pancreatic cancer cell lines to
MAb C595 is summarised in Table 2. Immunocytochemical
staining of CAPAN-1, CFPAC-1 and PANC-1 cell lines was positive
for MAb C595 (Figure 2A, B and C), but negative for control MAb
A2 (Figure 2D, E and F) or omitted primary MAb (data not
shown). These results indicate that high expression of target
antigens (MUC1) was found in metastatic and primary pancreatic
cancer cell lines.
Table 1 Intensity of immunohistochemical staining of pancreatic cancer
tissues and normal pancreas tissues
Tissue staining with C595 MAb
+++ ++ + –
Tumour 28 15 5 5
Normal pancreas 0 0 3 50
Cancer and normal tissue sections were collected from 53 pancreatic cancer patients.
 ¼negative staining; +¼weak staining; ++¼moderate staining; +++¼strong
staining.
A
C
B
D
Figure 1 Expression of MUC1 in pancreatic cancer tissues. MUC1
expression was assessed by immunohistochemistry. Representative pictures
are shown for immmunostaining with MAbs C595 (test) and A2 (control).
High expression of MUC1 was found in patient 1 staining with MAb C595
(A) and moderate expression was found in patient 2 staining with MAb
C595 (B), while no MUC1 expression was found in patient staining with
MAb A2 (C) or in normal pancreas (D).
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sImmunocytochemical staining appeared to localise to the cell
membranes and Confocal Microscopy confirmed this. The
Confocal results indicate that surface expression of MUC1 was
found in CAPAN-1 (Figure 2G), CFPAC-1 (Figure 2H) and PANC-1
(Figure 2I) using MAb C595, but not for MAb A2 (data not shown).
Flow cytometry analysis also demonstrated distinct differences in
the patterns of reactivity of the MAb C595 with three cancer cell
lines compared with control MAb as shown by the representative
histograms. There were positive shifts (increases in the intensity of
fluorescence) in the CAPAN-1 (Figure 2J), CFPAC-1 (Figure 2K)
Table 2 Summary of immunocytochemistry, flow cytometry, confocal microscope and cytotoxicity results
MUC1
Flow cytometry
a
Immunocytochemistry Gated % Median value Confocal microscope Cytotoxicity D0 value
CAPAN-1 ++ 95 40 ++ 4.5
CFPAC-1 +++ 99.5 500 +++ 3.8
PANC-1 +++ 98.5 80 +++ 4.3
 ¼negative staining; +¼weak staining; ++¼moderate staining; +++¼strong staining.
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Figure 2 Expression of MUC1 in pancreatic cancer cell lines. Representative pictures are shown for immmunostaining with MAbs C595 (test) and A2
(control). MAb C595 was strongly positive in three cell lines (A–C), while MAb A2 was negative in three cancer cell lines (D–F). Brown staining indicates
positive cells. The MUC1 cell surface expression in three cancer cell lines was confirmed by Confocal Microscope (G–I). Green staining indicates positive
cells. Expression of MUC1 in three viable pancreatic cancer cell lines was assessed by FACA analysis (J–L). Data are presented as histograms, using a mouse
IgG1-negative control to determine background fluorescence and to set the marker (M1). All of the photographs are at  200 magnification.
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sand PANC-1 (Figure 2L) cells stained with MAb C595. These
results indicate that the target antigen (MUC1), recognised by
MAb C595, are on the cell surface of viable cells, and confirm our
immunocytochemical observations.
213Bi-C595 inhibits pancreatic cancer cells proliferation in
vitro
Varying concentrations of
213Bi-C595 were added to the cultured
cell lines for 24h, and their effect on cell growth was assessed using
MTS assays in triplicate. D0 (37% cell survival) values of
213Bi-C595
are at 3.8, 4.5 and 4.3mCi in 300ml for three cell lines (Figure 3),
whereas the D0 values of
213Bi-A2 are at 60–69mCi, 13–18-fold,
respectively.
213Bi-C595 AIC inhibits the growth of the three
pancreatic cancer cell lines in vitro in a concentration-dependent
fashion. At the maximum dose of 10mCi, cell survival when treated
with
213Bi-C595 was reduced to 5–10%, while those treated with
nonspecific
213Bi-A2 AIC was 90–95%, and cDTPA-C595 or C595
MAb alone were more than 95%. The higher the overexpression of
MUC-1, the lower the D0 value (See Table 2).
213Bi-C595 induces apoptosis
After treatment with
213Bi-C595, the treated cells in the 96-well
plates showed typical apoptotic morphology, that is, cells became
rounded, shrunken and detached, whereas untreated controls and
cells treated with the nonspecific control
213Bi-A2 did not exhibit
apoptotic morphology. Representative morphological changes are
shown in Figure 4A–F. The exposed 30 OH ends of DNA
fragments generated by apoptotic DNA cleavage were detected
by TUNEL assay, in which the nonapoptotic cells stained green,
while apoptotic cells stained brown. A representative experiment is
shown in Figure 4G–L. After treatment,
213Bi-C595-treated cells
showed typical apoptotic morphology, whereas cells treated with
213Bi-A2 did not. The results are summarised in Figure 4.
213Bi-
C595 causes morphological changes of treated cancer cells and
induces apoptosis. The percentages of apoptotic cells are 11, 18, 42,
87, 92 and 81% at 4, 8, 12, 24, 48 and 72h after treatment with
10mCi10
5 cells
 1, respectively (Figure 5). However, the percentage
of apoptotic cells for nonspecific control groups remains low
(o15%).
DISCUSSION
Monoclonal antibody-based therapeutics is an important option to
control metastases and improve survival rate of pancreatic cancer.
These strategies include MAb combination with cytotoxic drugs,
conjugation with radionuclides or immunological effector cells.
High specification and affinity to targeted cancer tissue are
essential for the selection of targeted antigens and targeting
vectors.
In the present study, we first demonstrated the expression of the
MUC1 antigen on human pancreatic cancer specimens and human
pancreatic cancer cell lines using MAb C595. MUC1 is a mucin,
high MW glycoprotein. The biological function of MUC1 may be in
part due to its large size and the extended rigid structure. The
expression of MUC1 in tumours may function as an antiadhesion
molecule, which inhibits cell–cell adhesion, inducing a release of
cells from tumour nests and causing micrometastasis (Feng et al,
2002). Overexpression of MUC1 in cancer cells may effect efficient
lysis by cytotoxic lymphocytes and therefore contribute to escape
from immune surveillance (van de Wiel-van Kemenade et al,
1993). It has been proposed that enhanced levels of MUC1
expression by cancer cells may mask extracellular domains from
immune surveillance, confer a survival advantage on malignant
cells and play an important role in the ability of tumours to invade
and metastasise (Mommers et al, 1999; Hughes et al, 2000b). It was
also reported that increased MUC-1 expression correlates with the
stage and grade of pancreatic cancer. MUC1 upregulation was
significantly correlated to the depth of invasion, lymph node
metastasis and peritoneal dissemination (Satoh et al, 2000). In this
study, we found that over 90% of primary pancreatic tumours
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Figure 3 Representative cytotoxicity study of CAPAN-1 (A), CFPAC-1
(B) and PANC-1 (C) cells following treatment for 24h with
213Bi-C595.
Cells were treated with varying concentrations of
213Bi-C595 or nonspecific
control
213Bi-A2, incubated overnight and cell survival was measured by
MTS assay at 24h and expressed as a percentage of cell survival of control
cells. Results are expressed as a mean percent s.d. of control plates
containing nonspecific a conjugates. Each experiment was performed in
triplicate, and each point represents the mean of three experiments.
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sexpressed MUC1, while the majority of normal pancreases did not.
This finding is significant because this may provide a useful target
for TAT in postsurgical MRD while sparing the normal pancreas.
Using the MAb C595, we found MUC1 expression on the surface
of CAPAN-1, CFPAC-1 and PANC-1 cancer cells by flow
cytometric analysis and confocal microscopy. CAPAN-1 and
CFPAC-1 are metastatic cancer cell lines, while PANC-1 is a
primary cancer cell line. Overexpression of MUC1 was found in all
three cell lines, suggesting that this overexpression may involve
pancreatic cancer metastases and that cancer clones that escape
from primary tumours do not lose the MUC1 antigen. This means
that targeting by systemic radiolabelled MAb C595 may be
possible. Our results clearly indicated that MUC1 is an effective
tumour surface marker for targeting pancreatic carcinoma. The
overexpression of MUC1 can provide a good target for further
investigating in vitro efficacy.
Cytotoxicity of
213Bi-C595 to three pancreatic cancer cells
proved to be specific and concentration-dependent. Three cell
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Figure 4 Morphological changes in three cell lines incubated with
213Bi-C595 (A–C) for 24 hours. (D–F) Matched, untreated cells are shown. TUNEL
assays of CAPAN-1, CFPAC-1 and PANC-1 cells are shown in (G–I), and control in (J–L). Typical apoptotic cells with condensed or fragmented nuclei are
observed in treated cell lines, while control cells show normal shapes. All of the photographs are at  200 magnification.
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Figure 5 Observation of apoptosis in time course after treatment with
213Bi-C595 and
213Bi-A2 AICs. Blue and red columns represent
213Bi-C595
and
213Bi-A2, respectively. The PANC-1 cells were treated with
213Bi-C595
and
213Bi-A2 with concentrations of 10mCi10
5cells
 1, incubated at 4, 8, 12,
24, 48 and 72h, tested by TUNEL assay, and expressed as a percentage of
TUNEL-positive cells in total cells. Each experiment was performed in
triplicate, and each point represents the mean of three experiments.
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slines demonstrated a similar pattern of cell killing because the
expression of MUC1 on three cell lines is similar (see Table 2).
These results suggest
213Bi-C595 can target and kill 63% of
pancreatic cancer cells (monolayer) in vitro using a low dose
(3.8B4.5mCi). Using 10mCi of
213Bi-C595, only o10% cancer cells
can survive after treatment, while using the same activity of
213Bi-
A2, 490% cancer cells can survive. There was a 13B18-fold
difference in the 37% survival (D0) values in vitro for the test
213Bi-
C595 compared with a nonspecific control
213Bi-A2. There was no
cell killing for cDTPA-C595 and C595 groups. These results suggest
that only specific
213Bi-C595 can effectively target MUC1-positive
cancer cells.
The exact mechanism of cell killing using
213Bi-C595 is still not
clear. One explanation is that after binding the surface MUC1
antigen,
213Bi-C595 may form
213Bi-C595–MUC1 complexes at the
cell membrane, emitting a particles that kill pancreatic cancer cells
by causing double-DNA-strand breaks. Another possibility is that
the surface-bound
213Bi-C595–MUC1 complexes may be inter-
nalised, resulting in increased cell killing efficiency. Clearly, many
factors including antigen affinity and antigen density will also play
an important role in the killing of targeted antigen-positive cells,
since those with high density will attract more AIC and those with
higher antigen affinity may ‘hold on’ to increased levels of
radioactivity for a longer time period. The relative importance of
these factors (antigen density, antigen affinity and internalisation)
in the killing process has not yet been determined.
The most effective radiation treatments are those that not only
hit the intended target but also cause the greatest amount of lethal
or nonrepairable damage to DNA. Therefore, a particles are most
effective in this respect (Hall, 1994). A large number of in vitro and
in vivo experiments with a-immunotherapy have shown dramatic
superiority over b-immunotherapy as only a few a hits of the
nucleus are needed to kill cells (Scheinberg et al, 1982; Vaughan
et al, 1982; Allen, 1999; Kennel et al, 1999; McDevitt et al, 2000).
Using electron micrographs in studies of murine lymphoma,
Macklis et al (1992) have demonstrated bizarre blebbing patterns,
condensation of chromosomal material and internucleosomal
DNA fragmentation patterns characteristic of programmed cell
death (apoptosis) after treatment with AIC, and suggested that a-
particles may kill cells by apoptotic mechanisms. In this study, we
found typical morphologic changes and a high percentage of
TUNEL-positive cells in three pancreatic cancer cell lines after
treatment using
213Bi-C595 in vitro. These data suggest that the
lethal pathway for the three cell lines in vitro after TAT involves
apoptosis.
CONCLUSION
We have demonstrated moderate to strong MUC1 expression on
the majority of human primary tumours and pancreatic cancer cell
lines using MAb C595. MUC1 is therefore an ideal targeted antigen
for targeted a therapy using
213Bi-C595. This AIC can target and
selectively kill pancreatic cancer cells in vitro. The lethal pathway
involves apoptosis. The specific cytotoxic effects obtained in this
in vitro study suggest this AIC may target and kill the majority of
human primary and metastatic pancreatic cancer cells harbouring
moderate to strong MUC1 overexpression.
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